Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

10

Portfolio Exits

1

Funds

1

About LifeForce Ventures

LifeForce Ventures is a healthcare focused venture firm.

LifeForce Ventures Headquarters Location

106 Lincoln Boulevard No. 104

San Francisco, California, 94129,

United States

415-519-4017

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest LifeForce Ventures News

Glooker snags $7 mln

Jan 9, 2014

Glooko has closed $7 million in Series A-1 funding. Investors included Samsung Venture Investment Company, Lifeforce Ventures, The Social + Capital Partnership, Sundeep Madra and Yogen Dalal. Based in Palo Alto, Calif., Glooker is a provider of mobile diabetes management solutions. PRESS RELEASE Palo Alto, CA (PRWEB) January 08, 2014 Glooko Inc., makers of a FDA-cleared mobile diabetes management system, announced today it has raised $7 million in a Series A-1 round from several new investors including Samsung Venture Investment Company (SVIC) and Lifeforce Ventures as well as existing investors including The Social + Capital Partnership, Sundeep Madra and Yogen Dalal. Using this investment, Glooko will focus on enabling predictive diabetes care by delivering patient data and decision-making algorithms to health providers and payer groups. Samsung Venture Investment brings in strategic value given Samsung’s leadership position in the mobile market globally. “Over the last two years, Glooko has built a diabetes management infrastructure bent on liberating blood glucose data from glucose meters and making it accessible to patients and clinicians,” said Rick Altinger, Glooko’s CEO. “Our next steps are to scale Glooko’s system to global accessibility and to add a layer of analytics and messaging capable of making therapeutic recommendations for diabetes management. The investors who have contributed to this round will help us achieve these goals.” Glooko’s existing investors participated in this financing round with a strong vote of confidence in the company’s vision and direction. “We believe that Glooko can fundamentally disrupt the way diabetes is managed here in the US and other parts of the world,” said Chamath Palihapitiya, Founder & Managing Partner, Social + Capital. Glooko offers an FDA 510(k) cleared diabetes management system focused on making glucose data accessible to both patients and clinicians. The system includes the Glooko MeterSync Cable and Glooko’s mobile application – when combined, these tools allow for glucose data to be directly transferred from a glucose meter into a mobile device. The mobile apps integrate into the existing Glooko diabetes management web dashboards, which enable healthcare professionals and care management teams to remotely monitor and identify at-risk patients. Glooko is available on both the iOS and Android operating systems – the company received FDA 510(k) clearance for its Android system and launched it in November. Across both mobile operating systems, Glooko currently supports data transfer between 26 glucose meters and 27 mobile devices. By using Glooko’s population management and analytics tools, health systems and disease management organizations can increase focus on at-risk patients and achieve higher level of adherence to treatment plans among their diabetes population. Scripps Whittier Diabetes Institute is amongst notable health systems that are currently using Glooko’s diabetes management system. To learn more about Glooko’s enterprise-grade diabetes management system, email bizdev(at)glooko(dot)com. To reach Glooko’s Press Team, email press(at)glooko(dot)com. About Glooko Inc. Glooko is an innovative Silicon Valley startup with a unique diabetes management solution for patients, health systems, and payer groups. Glooko’s products – the Glooko mobile app, MeterSync Cable for iOS and Android, and Glooko Web Dashboard – enable clinicians to remotely access their patients’ blood glucose readings and related data. The company does so by allowing people with diabetes to download glucose readings to their smartphone. The company was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Chamath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Ventures, Judy Estrin, and Dr. Russell Hirsch. About Samsung Venture Investment Corporation Samsung Venture Investment Corporation manages investment and investment-related activities for Samsung affiliate companies. The investment mandate for Samsung Venture Investment Corporation tracks closely to the strategic priorities of Samsung affiliate companies’ core operating divisions, and encompasses investments in semiconductors, displays, telecommunications, and consumer electronics. © 2015 Buyouts Insider / Argosy Group LLC

LifeForce Ventures Investments

10 Investments

LifeForce Ventures has made 10 investments. Their latest investment was in Sonoma Biotherapeutics as part of their Series B on August 8, 2021.

CBI Logo

LifeForce Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/4/2021

Series B

Sonoma Biotherapeutics

$265M

Yes

28

4/25/2017

Series A - II

Circle Pharma

$2M

Yes

1

4/20/2016

Series B

Second Genome

$42.6M

Yes

9

3/30/2016

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/19/2015

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/4/2021

4/25/2017

4/20/2016

3/30/2016

8/19/2015

Round

Series B

Series A - II

Series B

Series B

Series A - III

Company

Sonoma Biotherapeutics

Circle Pharma

Second Genome

Subscribe to see more

Subscribe to see more

Amount

$265M

$2M

$42.6M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

28

1

9

10

10

LifeForce Ventures Portfolio Exits

1 Portfolio Exit

LifeForce Ventures has 1 portfolio exit. Their latest portfolio exit was Exa Health on September 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/7/2021

Acquired

$99M

3

Date

9/7/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

3

LifeForce Ventures Fund History

1 Fund History

LifeForce Ventures has 1 fund, including LifeForce Capital Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

LifeForce Capital Fund I

1

Closing Date

Fund

LifeForce Capital Fund I

Fund Type

Status

Amount

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.